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Abstract
The alpha-1-antitrypsin (A1AT) gene is highly polymorphic, with more than 100 genetic variants identified of which
some can affect A1AT protein concentration and/or function and lead to pulmonary and/or liver disease. This study
reports on the characterization of a p.G320R variant found in two patients, one with emphysema and the other with
lung cancer. This variant results from a single base-pair substitution in exon 4 of the A1AT gene, and has been char-
acterized as P by isoelectric focusing. Functional evaluation of the A1AT p.G320R variant was through comparing
specific trypsin inhibitory activity in two patients with pulmonary disorders, carriers of the p.G320R variant, and 19
healthy individuals, carriers of normal A1AT M variants. Results showed that specific trypsin inhibitory activity was
lower in both emphysema (2.45 mU/g) and lung cancer (2.07 mU/g) patients than in carriers of the normal variants
(range 2.51-3.71 mU/g). This rare A1AT variant is associated with reduced functional activity of A1AT protein. Con-
sidering that it was found in patients with severe pulmonary disorders, this variant could be of clinical significance.
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Alpha-1-antitrypsin(A1AT)isthemostabundantcir-
culatingplasmaserineproteinaseinhibitorandfunctionsas
amajorinhibitorofneutrophilelastaseinthelowerrespira-
torytract.ThegenecodingforA1ATspansover12.2kbon
chromosome 14, and is comprised of seven exons and six
introns (Crystal, 1990). The two parental A1AT genes are
codominantly expressed and contribute to A1AT serum
concentrations. Human A1AT is a 52 kDa, 394 amino-
acids-long acute phase glycoprotein composed of nine 
helices (A  I), three -sheets and a mobile reactive loop,
and is mainly synthesized in the liver (Lomas and Maha-
deva, 2002; Lomas and Parfey, 2004). The core of the reac-
tivecenterwithintheloopisrepresentedbytwoaminoacid
residues, Met-358 and Ser-359. The enzyme reacts as bait
or a mouse trap for its target proteinases. The complex be-
tween A1AT and its target is recognized by hepatic recep-
tors and cleared from circulation.
The A1AT gene is highly polymorphic, with more
than 100 genetic variants identified, so far (Luisetti and
Seersholm, 2004). A1AT protein variants are categorized
as normal, deficient, null or dysfunctional (American Tho-
racic Society/European Respiratory Society Statement,
2003). Deficient variants are associated with reduced
A1AT serum concentrations, undetectable in the case of
null variants. Dysfunctional variants are associated with
normalA1ATserumconcentrations,buthavealteredactiv-
ity against target proteinases. The most common mutated
A1AT variant is Z, which is categorized as both deficient
and dysfunctional (Brantly et al., 1996). Adequate concen-
trations and normal functioning of A1AT protein provide a
critical defense against proteolytic stress. Abnormalities in
both concentration and function of A1AT result in predis-
position to emphysema and in the development of cirrhosis
(Carrell and Lomas, 2002). The association of A1AT ge-
neticvariantswithseveralotherclinicalconditions,suchas
asthma, chronic obstructive pulmonary disease, lung can-
cer, pancreatitis and liver cancer, has also been reported
(Lomas and Parfrey, 2004; Yang et al., 2008).
This study reports on the functional evaluation of an
A1AT p.G320R variant found in two patients with severe
pulmonary disorders, emphysema and lung cancer. This
rare variant was previously described in one of 50 025 pa-
tients analyzed in a retrospective study in the USA
(Bornhorstetal.,2007).Inourstudy,thefunctionalevalua-
tion of the p.G320R variant was carried out by determining
specific trypsin inhibitory activity (STIA) in both patients
and19healthyindividuals,carriersofnormalA1ATalleles
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Short CommunicationM1, M2 and M3 (M1, M2, M3, M1M2 and M1M3). The
protocolwasapprovedbylocalresearchethicscommittees,
and informed consent was obtained from each participant
in the study.
The patient with emphysema was a 31-year-old male,
anon-smoker,withapasthistoryofrepeatedrespiratoryin-
fections in childhood. Chest X-ray and chest computed to-
mography (CT) scanning revealed hyper-inflated lung
fields with attenuation of peripheral vasculature, flattened
diaphragms and increased retrosternal clear space, with
patchy opacification in the upper part of the lungs. Aus-
cultation revealed weakened breathing-sounds with pro-
longed expiration. Pulmonary function tests revealed a se-
vere degree of ventilatory impairment (FVC of 81%
predicted, postbronchodilatator FEV1 of 29% predicted,
FEV1/FVC of 30% predicted). Arterial blood gas results
were normal as were diffusing capacity and diffusing coef-
ficient of the lung. Perfusion scintigraphy (scan) showed
bilateral zones of hypo-perfusion and defects. Sputum ex-
amination was positive for bacterial infection with Pseudo-
monasaeruginosa.Therewasnoevidenceofliverdisease.
The patient with lung cancer was a 73 year-old male,
smoker (240 pack years), with a positive family history of
chronic obstructive pulmonary disease and lung cancer,
and with clinical signs of Superior vena cava syndrome.
Microcellular lung carcinoma was diagnosed by bron-
choscopicbiopsyandbiopsyofthenecklymphnode.Chest
X-ray showed an enlargement of the upper mediastinum.
CT scanning confirmed a large (110 x 65 mm) mass caus-
ing compression of the vascular structure on the right lung,
with the enlargement of supraclavicular lymph nodes on
the right side. Pulmonary function tests revealed a severe
ventilatory impairment (FVC of 59% predicted, FEV1 of
36% predicted, FEV1/FVC of 46% predicted) and hypo-
xemia (PaO2 8.2 kPa) without hypercapnia in arterial
blood. Biochemical analyses, ultrasound and CT scanning
indicated normal liver morphology and function.
Isoelectric focusing (IEF) of serum proteins, per-
formed on the pH range 4.2-4.9, with the 2117 Multiphor
system (GE Healthcare) revealed the M1P phenotype in
both patients (Figure 1A).
The whole A1AT gene was analyzed by direct DNA
sequencing, using the ABI Prism BigDye Terminator Kit
(Applied Biosystems). Sequence analysis with Sequence
AnalysisSoftware(AppliedBiosystems)revealedthepres-
ence of a p.G320R (c.1030G > A) variant in both patients
(GenBank accession number EF683685) (Figure 1B). This
variant results from a single base-pair substitution of gua-
nine by adenine in exon 4 of the A1AT gene
(Gly-320[GGG]  Arg-320[AGG]). In both patients,
p.G320R occured on the common normal M1Val213 ge-
netic background.
Three-dimensional (3D) models of the A1AT wild-
type and p.G320R variant, generated using Swissmodel,
were analyzed by Matras Protein 3D Structure Comparison
(Guex and Peitsch, 1997; Kawabata, 2003). No structural
differencesbetweenwild-typeproteinandmutatedproteins
were observed.
In order to evaluate whether p.G320R variant has al-
tered activity in comparison to the wild type protein, spe-
cific trypsin inhibitory activity (STIA) values were deter-
minedinbothcarriersofA1ATp.G320Rvariant,aswellas
in 19 healthy individuals, carriers of normal A1AT alleles
M1, M2 and M3 (M1, M2, M3, M1M2 and M1M3). Serum
A1AT concentration was measured on NOR-Partigen
plates (Dade Behring). Serum trypsin inhibitory capacity
(TIC) was measured with N-benzoyl-dl-arginine-p-nitro-
aniline (BAPNA, Sigma) as substrate by the method of
DietzandcoworkerswhichwasadaptedforIL600Clinical
Chemistry Analyzer (Instrumentation Laboratory) (Dietz,
1976). All TIC measurements were performed in triplicate.
ToassessthefunctionalityofA1ATmoleculesandtoavoid
the influence of A1AT concentration, the STIA was calcu-
lated as the ratio between measured TIC values and serum
A1AT concentrations. Although according to the concen-
tration, the p.G320R variant appears not to be deficient, its
STIAvalueswerereducedinbothemphysema(2.45mU/g)
and lung cancer (2.07 mU/g) patients in comparison with
those obtained in healthy individuals (3.11  0.30 mU/g)
(Table 1).
Our study on functional evaluation of A1AT
p.G320Rvariantbydeterminationofspecifictrypsininhib-
itory activity demonstrated its reduced activity in compari-
son to normal A1AT M variants. Although molecular mod-
eling revealed no 3D differences between wild-type and
mutated protein, specific trypsin inhibitory activity of
p.G320R variant was significantly lower in comparison to
normal M variants. In the p.G320R variant, the mutated
amino acid is located outside the reactive center loop of the
protease inhibitor, in a hinge region between the I and the
5A sheet. The 5A sheet, together with 3A and neigh-
boring sites, is a part of the shutter region in the serpin mol-
ecule,thelatterbeingimportantincontrollingandmodulat-
ing conformational changes during sheet opening and
insertion of the conserved hinge of the reactive center loop
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Figure1-A.PhenotypingofA1ATinserumsamplesofpatientswithem-
physema (E) and lung cancer (LC) by isoelectric focusing. Major M and P
bands are denoted by arrows. B. DNA sequence of p.G320R variant.(Whisstocketal.,2000;Irvingetal.,2000).Numerousmu-
tants identified in the shutter region of the serpin molecule
lead to serpin dysfunction and subsequent serpinopathies
(Stein and Carrell, 1995). In the case of the p.G320R vari-
ant, there is the possibility that a more voluminous, posi-
tivelychargedaminoacid(Arg)replacingasmall,nonpolar
one (Gly) might influence conformation and thus affect
A1AT functional activity.
According to its migration pattern on IEF gels, the
p.G320RvariantphenotypehasbeencharacterizedasPand
recently denoted as Psalt lake (Bornhorst et al., 2007), but to
our best knowledge, nothing has been published regarding
further characterization of this rare variant. Several differ-
ent genetic variants have been shown to result in the “P”
phenotype, but they are indistinguishable by IEF, and
thereforehavenotbeenwellstudied.Thegroupof“P”vari-
ants includes those associated with reduced (Plowell,P duarte)
and normal (Pst albans,P budapest) serum A1AT concentrations,
butlittleisknownoninhibitoryactivityassociatedwithdif-
ferent “P” variants. One of the best studied “P” variants,
Plowell, is associated with reduced serum A1AT concentra-
tions and near normal inhibitory activity. It was also dis-
covered in a case of severe A1AT deficiency (Cook et al.,
1995). In our study, the p.G320R variant (Psalt lake) was
found in two patients with severe pulmonary disorders, and
was associated with reduced inhibitory activity.
Findings of this study, along with other studies re-
porting on variability of A1AT “P” phenotype, emphasize
the need for caution in clinical interpretation of results ob-
tained by IEF.
In summary, this study demonstrated impaired activ-
ity of serum A1AT in carriers of p.G320R variant, which
appearsnottobedeficient.Consideringthatitwasfoundin
patients with severe pulmonary disorders, this variant
might be of clinical significance. These findings should be
confirmed by analyzing the specific trypsin inhibitory ca-
pacity of recombinant A1AT p.G320R variant in order to
completely eliminate the influence of different physiologi-
cal factors that might interfere with protein activity.
Acknowledgments
This work was supported by grants 143051 and
145036 from the Ministry of Science. The authors wish to
thank Snezana Dobrivojevic (Health Centre ‘Stari Grad’
Belgrade), Aleksandar Krstic (Institute of Molecular Ge-
netics and Genetic Engineering), dr Slobodanka Kolun-
dzija (National Blood Transfusion Institute) and Dusanka
Necic (University Clinical Center Zvezdara) for their help
in conduction of this study.
References
American Thoracic Society/European Respiratory Society State-
ment (2003) Standards for the diagnosis and management of
individualswithalpha-1antitrypsindeficiency.AmJRespir
Crit Care Med 168:818-900.
Brantly M, Lee J, Hildesheim J, Uhm C, Prakash UB, Staats BA
and Crystal RG (1996) Alpha 1-antitrypsin gene mutation
hot spot associated with the formation of a retained and de-
gradednullvariant.AmJRespirCellMolBiol16:225-231.
Bornhorst JA, Calderon FRO, Procter M, Tang W, Ashwood ER
and Mao R (2007) Genotypes and serum concentrations of
human alpha-1-antitrypsin “P” protein variants in a clinical
population. J Clin Pathol 60:1124-1128.
CarrellRWandLomasDA(2002)Alpha-1-antitrypsindeficiency
- A model for conformational diseases. N Engl J Med
345:45-53.
Cook L, Burdon J, Brenton S, Janus ED and Knight K (1995) Al-
pha-1-antitrypsin PLowell: A normally functioning variant
present in low concentration. AustNZJM e d25:695-697.
Crystal RG (1990) Alpha 1-antitrypsin deficiency, emphysema,
and liver disease. Genetic basis and strategies for therapy. J
Clin Invest 85:1343-1352.
Dietz AA (1976) Use of -N-benzoyl-L-arginine-p-nitroanilide
as trypsin substrate in estimation of 1-antitrypsin. Clin
Chem 22:1754-1755.
Guex N and Peitsch MC (1997) SWISS-MODEL and the Swiss-
PdbViewer: An environment for comparative protein mod-
eling. Electrophoresis 18:2714-2723.
Irving JA, Pike RN, Lesk AM and Whisstock JC (2000) Phylog-
eny of the serpin superfamily: Implications of patterns of
amino acid conservation for structure and function. Genome
Res 10:1845-1864.
Kawabata T (2003) MATRAS: A program for protein 3D struc-
ture comparison. Nucleic Acids Res 31:3367-3369.
Lomas DA and Mahadeva R (2002) 1-antitrypsin polymeriza-
tion and the serpinopathies. Pathobiology and prospects for
therapy. J Clin Invest 110:1585-1590.
Lomas DA and Parfrey H (2004) Alpha1-antitrypsin deficiency.
4: Molecular pathophysiology. Thorax 59:529-535.
Luisetti M and Seersholm N (2004) Alpha1-antitrypsin defi-
ciency. 1: Epidemiology of alpha1-antitrypsin deficiency.
Thorax 59:164-169.
Stein PE and Carrell RW (1995) What do dysfunctional serpins
tellusaboutmolecularmobilityanddisease?NatStructBiol
2:96-113.
Analysis of p.G320R A1AT variant 7
Table 1 - Concentrations, trypsin inhibitory capacity (TIC) and specific inhibitory activity (STIA) of A1AT in healthy individuals with MM variants
(n = 19) and in patients-carriers of p.G320R variant.
A1AT genotype Concentration of A1AT (g/L) TIC (mU) STIA (mU/g)
MM 1.53  0.138 4.73  0.507 3.11  0.354
M1p.G320R-(emphysema patient) 0.97 2.37 2.45
M1p.G320R (lung cancer patient) 2.17 4.49 2.07Whisstock JC, Skinner R, Carrell RW and Lesk AM (2000)
Conformational changes in serpins. I. The native and clea-
ved conformations of 1-antitrypsin. J Mol Biol 296:685-
699.
Yang P, Sun Z, Krowka MJ, Aubry MC, Bamlet WR, Wampfler
JA, Thibodeau SN, Katzmann JA, Allen MS, Midthun DE,
et al. (2008) Alpha1-antitrypsin deficiency carriers, tobacco
smoke, chronic obstructive pulmonary disease, and lung
cancer risk. Arch Intern Med 168:1097-1103.
Internet Resources
Swiss-PdbViewer Application, http://www.expasy.org/spdbv
(June 5, 2008).
Associate Editor: Francisco Mauro Salzano
License information: This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
8 Ljujic et al.